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Abstract 
Poly (lactide-co-glycolide) (PLGA) microspheres have been used for regenerative medicine due to their 
ability for drug delivery and generally good biocompatibility, but they lack adequate bioactivity for bone 
repair application. CaSiO3 (CS) has been proposed as a new class of material suitable for bone tissue 
repair due to its excellent bioactivity. In this study, we set out to incorporate CS into PLGA 
microspheres to investigate how the phase structure (amorphous and crystal) of CS influences the in 
vitro and in vivo bioactivity of the composite microspheres, with a view to the application for bone 
regeneration. X-ray diffraction (XRD), N2 adsorption-desorption analysis and scanning electron 
microscopy (SEM) were used to analyze the phase structure, surface area/pore volume, and 
microstructure of amorphous CS (aCS) and crystal CS (cCS), as well as their composite microspheres. 
The in vitro bioactivity of aCS and cCS – PLGA microspheres was evaluated by investigating their 
apatite-mineralization ability in simulated body fluids (SBF) and the viability of human bone 
mesenchymal stem cells (BMSCs). The in vivo bioactivity was investigated by measuring their de novo 
bone-formation ability. The results showed that the incorporation of both aCS and cCS enhanced the in 
vitro and in vivo bioactivity of PLGA microspheres. cCS/PLGA microspheres improved better in vitro 
BMSC viability and de novo bone-formation ability in vivo, compared to aCS/PLGA microspheres. Our 
study indicates that controlling the phase structure of CS is a promising method to modulate the 
bioactivity of polymer microsphere system for potential bone tissue regeneration. 
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INTRODUCTION 
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Microspheres have received significant attention recently as an injectable material for bone tissue 
regeneration.1,2 The main advantage of this approach, when compared with the traditional block 
scaffolds, is that minute microspheres can be combined with a drug vehicle and be administered by 
injection, opening up the possibility of filling defects of various shapes and sizes through minimally 
invasive surgery. When implanted, the microspheres system is expected to easily conform to an irregular 
implant site.3 The ideal properties for a microsphere system for bone regeneration is to combine 
bioactivity with a capacity for controlled protein/drug-delivery.4,5 To this end, a number of different 
materials, including inorganic Ca-P ceramics3,6 and polymers7,8 have been manufactured into 
microspheres for the purposes of drug delivery and bone tissue repair applications. Of these materials, 
ceramic microspheres, such as hydroxyaptite (HAp) ceramics are bioactive, but do not possess 
controllable protein/drug release and have less than optimal degradation kinetics.3,6,9 Poly 
(lactide-co-glycolide) (PLGA)-based microsphere system is a potential drug carrier for bone tissue repair 
as PLGA is biodegradable with generally good biocompatibility.10,11 As a true bone tissue engineering 
material, the bioactivity PLGA microspheres falls well short of being ideal.12,13 A bioactive 
ceramic/PLGA composite material combines the bioactivity of the former with the drug/protein release 
properties of the latter, and presents one of best options for developing microsphere system for bone 
repair applications.7,14 
Wollastonite (CaSiO3; CS) ceramics combine high bioactivity with degradability,15 and previous studies 
have shown that bioactive wollastonite coating on Ti alloys form an excellent bond with host bone.16,17 
Xu et al. showed that wollastonite ceramic scaffolds have improved degradation and bone-formation 
ability compared to traditional β-tricalcium phosphate ceramics when implanted in a rabbit calvarial 
defect model.18 It has been demonstrated that incorporating crystal CS (cCS) into PHBV microspheres 
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creates a composite material with greatly enhanced the hydrophilicity and the proliferation and 
differentiation potential of bone cells.19-21 According to these results, we hypothesized that incorporating 
CS into PLGA polymer microspheres would result in a material with significantly enhanced in vitro and 
in vivo bioactivity. Although there are earlier studies of cCS ceramics and their composites,15,16,18-21 as 
far as we know, no previous studies have explored how the phase structure of amorphous CS (aCS) and 
crystal CS (Ccs) influences the in vitro and in vivo bioactivity of polymer microspheres. The basis for 
this hypothesis is the fact that the phase structure of bioactive ceramics greatly influences its bioactivity 
and rate of degradation. Therefore, the aims of this study were therefore to investigate how the phase 
structure of CS influences the in vitro and in vivo bioactivity of PLGA microspheres. 
 
MATERIALS AND METHODS 
Preparation and characterization of CaSiO3 powders 
Amorphous and crystal CS powders were synthesized by a chemical precipitation method.22 Briefly, 
calcium nitrate tetrahydrate (Ca(NO3)2·4H2O, (Sigma-Aldrich, Castle Hill, NSW, Australia) was 
dissolved in distilled water (0.1 M), adjusted to pH 12 using NH3·H2O, to obtain the Ca containing 
solutions. A 0.1 M sodium metasilicate (Na2SiO3) (Sigma-Aldrich) solution was added dropwise to the 
Ca containing solution while stirring, to produce a white precipitate. After stirring for 12 h, the 
precipitate was filtered, and washed three times with distilled water followed by one-time wash with 
ethanol. The remaining liquid was removed by vacuum filtration, and the precipitate was dried at 60ºC 
for 24 h, the resulting powders, amorphous CaSiO3, are hereafter referred to aCS. Crystal CaSiO3, 
(hereafter referred to as cCS), was obtained by subjecting aCS to 800ºC heat for 2 h; both the aCS and 
cCS powders were ground and sieved to 230 meshes. The size distribution of amorphous and crystal CS 
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particles synthesized by this method is around 0.1-0.3 μm and 0.3-5μm, respectively. 
The phase and microstructure of aCS and cCS powders were characterized by X-ray diffraction (XRD) 
and scanning electron microscopy (SEM). Brunauer-Emmett-Teller and Barret-Joyner-Halenda were 
used to determine the surface area, the pore size distribution and the pore volume of aCS and cCS 
powders by N2 adsorption-desorption analysis. 
 
Preparation and characterization of CS/PLGA microspheres 
PLGA, aCS/PLGA and cCS/PLGA microspheres were prepared by a double emulsion method. 
aCS/PLGA microspheres were typically prepared in a two step procedure: 2.4 g of PLGA 
(lactide:glycolide = 85:15) was first dissolved in 60 ml of 4% (w/v) chloroform, then 0.36 or 0.72 g of 
aCS powders was added to the PLGA/chloroform solution (concentrations of CS/PLGA: 15% or 30%) 
under constant stirring; the mixture was stirred for 30 min and then sonicated for 10 min, which 
produced a uniform emulsion. This mixture was then added to 300 ml of 0.5% polyvinyl alcohol (PVA) 
solution under a stirring rate of 1000 rpm for 1 h. The particles were collected by centrifugation at 5000 
rpm for 5 min, washed 3 times in ddH2O, then dried in a vacuum at 40ºC for 2 days to obtain aCS/PLGA 
microspheres. 
cCS/PLGA and pure PLGA microspheres were prepared in a same way as the aCS/PLGA. The 
composition and morphology of the prepared microspheres were characterized by SEM and 
energy-dispersive spectrometer (EDS).  
 
The effect of CS microstructure on the mineralization  
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The surface mineralization of the three microspheres was investigated using acellular simulated body 
fluids (SBF). The SBF was prepared according to previous publications 23 and 0.3 g of microspheres 
were immersed in 200 mL of SBF and kept at 37 ºC for various time points. The microspheres were 
soaked for 7 days and analyzed by SEM and EDS to determine their apatite-forming capacity. The pH of 
the SBF solution was tested after soaking the microspheres, without refreshing the solution. The 
concentration of Ca and Si ions released from the microspheres was determined by inductively coupled 
plasma atomic emission spectroscopy (ICP-AES). As we found that both crystal 15%CS-PLGA and 
amorphous 15%CS-PLGA microspheres had no apatite formation in SBF due to the low contents of CS 
in the microspheres, therefore, we selected 30%CS/PLGA microspheres for the further in vitro and in 
vivo testing. 
 
The effect of CS microstructure on BMSCs viability  
Human bone mesenchymal stem cells (BMSCs) were isolated from bone marrow samples (n = 5) 
following a protocol described previously.24 All samples were obtained from patients at the Prince 
Charles Hospital, Brisbane, after informed consent was given; the project had the approval of the Ethics 
Committee of the Queensland University of Technology. The effect of microspheres on BMSCs viability 
was evaluated in a 6-well Transwells cell culture system (pore size for 0.4µm membrane). A schematic 
illustration of how the microspheres were loaded in this system is shown in Figure 1. With this culture 
system the released Ca and Si ions, as well as degradation products from the microspheres, will be 
dissolved into the cell culture medium, but the microspheres will not be in direct contact with the cells. 
PLGA, 30% amorphors CS/PLGA or 30% cCS/PLGA microspheres (15 or 25mg) were loaded onto the 
transwell membrane and incubated with 1x105 BMSCs at 37ºC in 5% CO2 for 1 or 7 days. Cell 
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morphology was studied by light microscopy and the cell viability were measured by MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method: 500 μl of 0.5 mg/ml MTT 
solution was added in each well and incubated for 4 h at 37ºC. The reaction was terminated by the 
addition of dimethyl sulfoxide and formazan concentration was measured in a plate reader at 495 nm. 
The results were expressed as the absorbance reading from each well less the optical density value of a 
blank. 
 
The effect of CS microstructure on the in vivo osteogenesis 
The bone forming ability of the different microsphere types was assessed in a calvarial defect model in 
severe combined immunodeficient (SCID) mice, following a previous described method.25 The surgeries 
were carried out according to the guidelines of the Animal Research and Care Committee of the Herston 
Medical Research Centre and the Queensland University of Technology. The surgical procedures were 
performed in aseptic conditions under general inhalation anesthesia. Briefly, a linear incision (1 cm long) 
was made in the left skull to reveal the bone surface. The periosteum was dissected from the bone 
surface and a full-thickness calvarial bone defect, 3 mm in diameter, was created with a trephine bur 
using a slow-speed dental drill. To avoid tissue damage due to overheating, 0.9% saline was dripped onto 
the contact point between the bur and bone and great care was taken to avoid injury to the dura mater. 
The microspheres were carefully placed into the defects and soft tissue above the defect was covered by 
the skin which was closed with skin staples.  
The animals were euthanized 8 weeks after surgery and the defect areas were collected. The samples 
were fixed in 4% paraformaldehyde for 12 h at room temperature. All samples were scanned for bone 
formation within the defect site using a µCT40 imaging system (Scanco Medical, Bassersdorf, 
 8
Switzerland) with the following scan parameters: 20 mm field of view, 55 kVp X-ray energy setting, 
1024 reconstruction matrix, slice thickness 0.02 mm, and a 250 ms integration time. Mineralized tissue 
was segmented from non-mineralized tissue using a global thresholding procedure with a value 
approximating 1.20 g/cm3 (150 on micro-CT) (25% lower than 1.6 g/cm3) which is the mineral density 
of healthy human compact bone. Bone volume per defect (BV; mm3) was recorded as the measure of 
defect bone regeneration. After the µCT scanning, all tissue samples were decalcified in 10% EDTA, 
changed twice weekly, for 2 to 3 weeks, after which they were embedded in paraffin. Serial sections with 
the thickness of 5 µm, were cut and mounted on polylysine-coated microscope slides. All sections were 
stained with hematoxylin and eosin (H & E), and a general assessment of the tissue and wound healing 
was performed using a light microscope.  
 
Statistical analysis 
 The data was expressed as means ± standard deviation (SD) for all experiments and were analyzed 
using One-Way ANOVA with a Post Hoc test. A p-value<0.05 was considered statistically significant. 
 
RESULTS 
Characterization of aCS and cCS powders 
The phase structure of CS powders before and after 800ºC calcination is shown in Figure 2. aCS showed 
a weak and wide diffraction peak (Fig. 2a), whereas cCS showed a strong and sharp characteristic peak 
of β-CS after calcining (Fig. 2b). As would be expected, aCS has a different microstructure compared to 
cCS (Fig. 3). aCS has uniform micropartilces (Fig. 3a), the cCS has aggregated particles (Fig. 3b). N2 
adsorption-desorption isotherms and the corresponding pore distribution analysis for aCS and cCS 
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powders are listed in Figure 4. aCS shows an obvious isotherm pattern and the pore distribution mainly 
focuses on 40 nm (Fig. 4a); cCS has overlapping adsorption and desorption curves and a disordered pore 
distribution (Fig. 4b). The surface area and pore volume of aCS (108.8m2/g and 0.61cm3/g) are 
significantly higher than those of cCS powders (4.4cm3/g and 0.02cm3/g) (Table 1). 
 
Characterization of CS/PLGA microspheres 
SEM analysis shows, that the size distribution of the microspheres, has a size range of 5–10 µm (Figure 
5). Pure PLGA microspheres have a smooth surface and no obvious Ca and Si peaks in their EDS pattern. 
By contrast, after incorporating 30% aCS and cCS into PLGA microspheres, some CS particles exist on 
the surface of PLGA microspheres and EDS analysis shows the obvious signal of Ca and Si (Fig. 5c and 
e). The ratio of Ca/Si in aCS/PLGA and cCS/PLGA microspheres is 0.96 and 0.99, respectively, 
confirming that CS has been incorporated into PLGA. However, there is no obvious CS particle 
distribution on the surface of 15%CS/PLGA microspheres due to the low contents of CS (Fig. 5b and d). 
 
The effect of CS microstructure on the mineralization 
SEM morphology and EDS analysis for the three microspheres types after soaking in SBF for 7 days are 
shown in Figure 6. The surface of PLGA microspheres has no obvious apatite mineralization deposition 
(Fig. 6a). A few apatite particles have formed on the 30%-cCS/PLGA microspheres and the P element 
signal is weak in EDS pattern (Fig. 6c). 30%-aCS/PLGA microspheres, however, show strong 
apatite-mineralization ability (Fig. 6b) and the formed apatite has a typical lathlike morphology with 
nano-size structure (Fig. 6d). EDS analysis shows the strong Ca and P peaks for the formed apatite on 
30%-aCS/PLGA microspheres, and the ratio of Ca/P is 1.54 (Fig. 6b). However, there is no obvious 
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apatite formation on the surface of amorphous 15%-CS/PLGA and crystal 15%-CS/PLGA microspheres 
(Fig. 6e and f).  
CS had an obvious effect of stabilizing the pH value of the SBF solution (Fig. 7). Pure PLGA 
microspheres induce a significant decrease in pH of the SBF. The pH is more stable when CS is 
incorporated into PLGA microspheres, with aCS having a greater ability to buffer the pH of SBF 
compared to cCS. The Ca and Si ions concentrations clearly show that aCS/PLGA microspheres have a 
faster Si ion release than cCS/PLGA microspheres (Table 2). 
 
The effect of CS microstructure on BMSCs viability  
The morphology of the BMSCs cultured in the Transwell culture system is shown in Figure 8. On day 1, 
there is no morphological difference of BMSCs cocultured with any of the microspheres, nor is there any 
apparent difference in the cell density (Fig. 8a). By day 7, the cells in all wells have clearly proliferated 
compared to day 1 (Fig. 8b). The MTS assay shows that incorporating CS powders into PLGA enhances 
BMSC viability after 7 days of culture, and that the rate of proliferation was greater when grown in a 
cCS/PLGA microspheres coculture compared to the PLGA and aCS/PLGA microsphere cocultures (Fig. 
9).  
 
The effect of CS microstructure on new bone formation 
Histological analysis and µCT measurement showed that both aCS and cCS-incorporated PLGA 
microspheres enhanced de novo bone-formation ability compared to pure PLGA microspheres, and that 
the average amount of bone tissue formed by cCS/PLGA microspheres was significantly higher than that 
generated by aCS (Fig. 10 and 11). In the aCS/PLGA microspheres group, the defect was bridged by thin 
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trabeculae of woven bone contacting granules surrounded mainly by connective tissue. The centre of the 
defects contained only connective tissue and biomaterial. This contrasted with cCS/PLGA microsphere 
group, here large amounts of freshly deposited and immature bone tissue was found in areas where the 
cCS/PLGA microspheres had been resorbed (Fig. 10). 
 
DISCUSSION 
In this study we have explored the effect of the phase structure (amorphous and crystal) of CS on the in 
vitro and in vivo bioactivity of PLGA microspheres. We found that aCS had significantly higher surface 
area and nano-pore volume than cCS. Despite the significantly different physical properties of aCS and 
cCS, the incorporation of aCS and cCS both significantly enhanced the in vitro and in vivo bioactivity of 
PLGA microspheres. aCS had greater apatite-mineralization ability in SBF environment compared to 
cCS; however, cCS/PLGA had greater BMSC viability in vitro and new bone-formation ability in vivo 
compared to the aCS/PLGA microsphere system. This study indicates that altering the phase structure of 
CS is a promising method to control the bioactivity of polymer microsphere system for potential bone 
tissue regeneration. 
A double emulsion method was used in this study to prepare CS/PLGA composite microspheres. 
Compared to other methods, such as electrostatic spraying,26 the advantage of a double emulsion method 
is that it is easy both to prepare and control the size of the microspheres. Our study showed that 
CS/PLGA microspheres had a relatively uniform size distribution (5-10µm). The small size and 
uniformity of these composite microspheres will significantly improve the injectability compared to the 
larger sized microspheres which typically result from electrostatic spraying.26,27  
Although aCS and cCS have identical chemical composition, their physical properties are very different, 
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in particular crystanillinity, surface areas, and nanopore structure and size. The principal reason for the 
different physical properties is that cCS has been treated at high temperature, leading to a particle 
aggregation (Fig. 3) which results in decreased surface area and pore volume (Table 1). The greater 
surface area and pore volume of aCS lead to a faster dissolution rate than cCS (Table 2). Bioactivity is an 
important issue when considering the chemical interactions between an implant material and the bone 
tissue. The chief disadvantages of PLGA are that its bioactivity is less than optimal and the material’s 
degradation products lead to an acidic environment which may elicit an inflammatory response.28-30 The 
incorporation of CS into PLGA microspheres improves the apatite-mineralization ability of PLGA 
microspheres and buffers the pH environment of SBF. Interestingly, aCS/PLGA microspheres have better 
apatite-mineralization ability and pH-stability than cCS/PLGA and pure PLGA microspheres. According 
to the mechanism of apatite formation on CS based ceramics,31-33 a plausible explanation for this is most 
likely that aCS releases more Ca and Si ions into the SBF solution and has a higher surface area than 
cCS. This results in the formation of more Si-OH groups on the surface of aCS, compared to that formed 
on cCS, which may contribute to inducing more apatite deposition on the surface of the aCS/PLGA 
microspheres. Similarly, the higher release of Ca and Si ions from aCS/PLGA microspheres more 
effectively buffers the decrease in pH than that of cCS/PLGA microspheres, by neutralizing the acidic 
degradation products of the PLGA microspheres. 
A Transwell cell culture system was used in this study to evaluate how the degradation products of 
microspheres, including Ca, Si ions and by-products from PLGA, affected BMSC viability (see Fig. 1). 
The results indicate that the incorporation of CS into PLGA microspheres enhanced cell viability. The 
most likely explanation for this is that CS buffered the pH of cell culture medium, which was beneficial 
for BMSC growth.34,35 Interestingly, cCS/PLGA microspheres seemed to have a more beneficial effect 
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on cell viability compared to aCS/PLGA microspheres. Similarly, both aCS and cCS enhanced the in 
vivo bone formation of PLGA microspheres, and in a similar fashion, cCS/PLGA microspheres increased 
bone formation capacity more than did aCS/PLGA microspheres. Previous studies have shown that, at a 
certain concentration range, Ca and Si ions actually stimulate cell proliferation.32,36 cCS/PLGA 
microspheres may possibly provide an ionic environment which is more suitable for BMSCs and in vivo 
bone formation than does the aCS/PLGA system. It is, however, intriguing that cCS/PLGA microspheres 
have lower apatite-mineralization ability than the aCS/PLGA microspheres in SBF; these data seem to 
be contradictory to the in vivo results, which suggest that the SBF method has limitations when used to 
evaluate the in vitro bioactivity of biomaterials.37,38 The in vivo bone formation ability is not only 
modulated by the apatite mineralization, but also by their ionic environment, for example, ion 
concentrations. To optimize the apatite-mineralization ability and ionic environment and further improve 
the bone-formation ability of CS/PLGA microspheres, two potential ways will be applied in our future 
study. One is to prepare amorphous and crystal CS composite particles firstly, and then the CS composite 
particles are incorporated into PLGA microspheres; the other way is to directly mix amorphous 
CS/PLGA microspheres and crystal CS/PLGA microspheres. The common aim of two potential ways is 
to harness the difference between amorphous CS and crystal CS in apatite mineralization and dissolution 
(or ion release), which is to optimize the in vivo bone-formation ability of CS/PLGA microspheres. 
 
CONCLUSIONS 
CS powders with amorphous or crystal phase structure were successfully incorporated into PLGA 
microspheres. The phase structure of CS is one of important factors to modulate the bioactivity of PLGA 
microspheres. Amorphous CS has induced an improved apatite mineralization on the surface of PLGA 
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microspheres, compared to crystal CS, but cCS/PLGA microspheres improved in vitro BMSC viability 
and in vivo new bone-formation in mouse, compared to aCS/PLGA microspheres. Our study indicates 
that controlling the phase structure of CS is a promising method to control the bioactivity of PLGA 
microsphere as injectable materials for potential bone tissue regeneration application. 
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Figure Captions 
Figure 1. Schematic illustrations of microspheres loaded in transwells system for cell culture. The released Ca, Si ions 
and degradation byproducts from microspheres will be dissolved in culture medium and response with cells; however, 
the microspheres will not directly contact with cells. 
Figure 2. XRD pattern for CaSiO3 powders before (a) and after (b) calcining at 800oC. 
Figure 3. SEM morphology for CaSiO3 powders before (a) and after (b) calcining at 800 oC. Arrow points to aggregated 
particles. 
Figure 4. N2 adsorption-desorption isotherms and the corresponding pore distribution analysis for (a) amorphous and (b) 
crystal CaSiO3 powders. The surface area and pore volume of amorphous and crystal CaSiO3 powders are listed in 
Table 1. 
Figure 5. SEM and EDS analysis for PLGA (a), amorphous 15%-CS/PLGA (b), amorphous 30%-CS/PLGA (c), crystal 
15%-CS/PLGA (d), and crystal 30%-CS/PLGA (e) microspheres. Arrows point to CaSiO3 particles in microspheres. 
The ratio of Ca/Si in amorphous 30%-CS/PLGA and crystal 30%-CS/PLGA microspheres is 0.96 and 0.99, 
respectively. 
Figure 6. SEM and EDS analysis for PLGA (a), amorphous 30%-CS/PLGA (b, d), crystal 30%-CS/PLGA (c),  
amorphous 15%-CS/PLGA (e), and crystal 15%-CS/PLGA (f) microspheres after soaking in SBF for 7 days. (d) is 
higher magnification picture for apatite formation on amorphous 30%-CS/PLGA microspheres. PLGA microspheres did 
not show obvious P element peak (a), crystal 30%-CS/PLGA microspheres showed a weak peak of P (c) and amorphous 
30%-CS/PLGA microspheres showed more obvious peak of P elements (b). The ratio of Ca/P for apatite on amorphous 
30%-CS/PLGA and crystal 30%-CaSiO3/PLGA microspheres is 1.54 and 1.97, respectively. However, there is no 
obvious apatite formation on the surface of amorphous 15%-CS/PLGA (e) and crystal 15%-CaSiO3/PLGA (f) 
microspheres. 
Figure 7. pH value change for SBF solution with soaking PLGA, amorphous CaSiO3/PLGA and crystal CaSiO3/PLGA 
(c) microspheres. The SBF solution with amorphous CaSiO3/PLGA microspheres has a more stable pH value than pure 
PLGA and crystal CaSiO3/PLGA microspheres. 
Figure 8. BMSCs growth in the transwell culture system loaded with different weight (15mg and 25mg) of PLGA, 
amorphous CaSiO3/PLGA and crystal CaSiO3/PLGA microspheres for 1 (a) and 7 (b) days. “15” and “25” stand for 15 
and 25mg (the weight) of the corresponding microspheres. “Blank” stands for blank control without adding any 
microspheres. 
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Figure 9. The viability of BMSCs in the transwell culture system loaded with PLGA, amorphous CaSiO3/PLGA and 
crystal CaSiO3/PLGA microspheres for 7 days. The incorporation of CaSiO3 powders into PLGA enhanced BMSC 
viability. BMSCs viability in crystal CaSiO3/PLGA microspheres is higher than that in PLGA and amorphous 
CaSiO3/PLGA microspheres. “15” and “25” stand for 15 and 25mg (the weight) of the corresponding microspheres. 
“Blank” stands for blank control without adding any microspheres. 
Figure 10. The in vivo bone formation was assessed by H&E. (a) and (b) for PLGA microspheres; (c) and (d) for 
amorphous CaSiO3/PLGA microspheres; (e) and (f) for crystal CaSiO3/PLGA microspheres. (a), (c) and (e) are low 
magnification images by 4 times (×4); (b), (d) and (f) are higher magnification images by 40 times (×40). Crystal 
CaSiO3/PLGA microspheres have more new bone formation than PLGA and amorphous CaSiO3/PLGA microspheres. 
Figure 11. The new bone volume in the defects implanting three microspheres by Micro-CT analysis. Both amorphous 
CaSiO3 and crystal CaSiO3 enhance the bone formation ability of PLGA microspheres. Crystal CaSiO3/PLGA 
microspheres have an improved bone formation ability than amorphous CaSiO3/PLGA microspheres. 
 
 
 
 
Table 1. The surface area and pore volume of amorphous and crystal CaSiO3 powders. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. The concentrations of Ca and Si ions for PLGA, amorphous CaSiO3/PLGA and crystal CaSiO3/PLGA 
microspheres. 
 
microspheres Si (ppm) Ca (ppm) 
30% aCS/PLGA 20.0 90.1 
30% cCS/PLGA 8.8 92.1 
PLGA 0 101.3 
 
CaSiO3 powders Surface area (m2/g) Pore volume (cm3/g) Pore size (nm) 
Amorphous 108.8 0.61 40 
Crystal 4.4 0.02 -- 
